Bildkälla: Stockfoto

Xbrane Biopharma: Xciting and Increasingly Compelling Case - Redeye

Redeye returns with an updated assessment and a raised fair value range for Xbrane following the announced licensing deal with Biogen.

Redeye returns with an updated assessment and a raised fair value range for Xbrane following the announced licensing deal with Biogen.
Börsvärldens nyhetsbrev
ANNONSER